|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
DAEWOONG PHARMACEUTICAL CO.,LTD.
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name DAEWOONG PHARMACEUTICAL CO.,LTD. Headquarters 223-23, SANGDAEWON 1-DONG, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO; Seongnam; Gyeonggi; 462807 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational Financial Auditors: Deloitte Touche Tohmatsu (2011) Incorporation Date: October 1, 2002 Total Employees: 1,309 Tel: 031-741-7700 |
|
Company Description |
| Sales drastically increased over the year-earlier period thanks to the steady growth of main products and launch of new products under co-promotion.Profitability was improved due to drastic fall of corporate tax despite expanding sales and admin expenses due to cost ratio, payroll, sales commission, advertising and promotion cost.Product lineup is balanced through product diversification as sales share of main product Olmetech declined. Stable business growth is expected with strong sales of Woorusa | ||
|
||
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
FULL COMPANY PROFILE
|
|
2012 Y (non-cons) |
2012 H1 (non-cons) |
|
 | ||
| Audited | Audited | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
XXX |
XXX |
| ||
Current Assets |
XXX |
XXX |
| ||
Total Liabilities |
XXX |
XXX |
| ||
Shareholders Equity |
XXX |
XXX |
| ||
Current Liabilities |
XXX |
XXX |
| ||
| * All the accounts are in KRW. | ||
Income Statement
| ||
Total Operating Revenue |
XXX |
XXX |
| ||
Operational Profit (Loss) |
XXX |
XXX |
| ||
Net Profit (Loss) |
XXX |
XXX |
| ||
| * All the accounts are in KRW. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
XXX |
XXX |
| ||
Return on Equity (ROE) |
XXX |
XXX |
| ||
Return on Sales (ROS) |
XXX |
XXX |
| ||
Return on Capital |
XXX |
XXX |
| ||
Gross Profit Margin |
XXX |
XXX |
| Efficiency Ratios | ||
| ||
Current asset turnover |
XXX |
XXX |
| ||
Asset Turnover |
XXX |
XXX |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
XXX |
XXX |
| ||
EBITDA |
XXX |
XXX |
| ||
Bookvalue (BV) |
XXX |
XXX |
| Liquidity Ratios | ||
| ||
Current Ratio |
XXX |
XXX |
| ||
Quick ratio |
XXX |
XXX |
| ||
Doom's day ratio |
XXX |
XXX |
| ||
Cash Flow to Debt |
XXX |
XXX |
| Leverage Ratios | ||
| ||
Leverage ratio |
XXX |
XXX |
| ||
Interest Coverage Ratio |
XXX |
XXX |
| ||
Debt to equity |
XXX |
XXX |
| ||
Debt to total assets |
XXX |
XXX |
| ||
Long Term Debt to Capital |
XXX |
XXX |
| Market ratios | ||
| ||
Price/Book Ratio |
XXX |
XXX |
| Trend Ratios | ||
| ||
Revenue Trend |
XXX |
XXX |
| ||
Net Income Trend |
XXX |
XXX |
| ||
 |